Ami Organics IPO subscribed 1.9x, Vijaya Diagnostic 0.3x on Day-1


While Ami is a pharma-focused specialty chemicals firm, Vijaya Diagnostic is among the largest diagnostic chains in southern India

Topics

IPO | Share price



BS Reporter 



Ami Organics’ IPO garnered 1.9 times subscription, while that of Vijaya Diagnostic was subscribed 30 per cent on Wednesday, the first day of the issue. Both IPOs close on Friday. Ami is a specialty chemicals firm focused on the pharma industry. Its IPO comprises Rs 200 crore fresh fund raise Rs 370 crore secondary share sale. The price bfor its IPO is Rs 603-610 per share. At the top-end the company will have a market cap of Rs 2,223 crore is valued at 41.2 times its FY21 earnings. Vijaya Diagnostic is among the largest diagnostic chains in southern India.

Its IPO is entirely a secondary share sale worth Rs 1,894 crore.

Vijaya’s price bis Rs 522 to 531 per share. At the top-end, the company will have a market cap of Rs 5,414 crore will be valued at 63.8 times its FY21 earnings.

MapMyIndia files papers with Sebi Digital mapping company MapMyIndia, which powers Apple maps, has filed preliminary papers with capital market regulator Sebi to raise funds through an initial share-sale. The IPO is entirely an offer for sale of up to 75,47,959 equity shares by existing shareholders a promoter, according to draft red herring prospectus (DRHP). The offer for sale (OFS) comprises sale of up to 30,70,033 equity shares by Rashmi Verma, up to 20,26,055 equity shares by Qualcomm Asia Pacific Pte Ltd up to 10,27,471 equity shares by Zenrin Co. It is looking to raise Rs 1,200-1,300 via IPO. (PTI)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism subscribe to Business Standard.

Digital Editor



First Published: Wed, September 01 2021. 18:07 IST



Source link